Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
JSPR | US
-0.93
-5.47%
Healthcare
Biotechnology
30/06/2024
04/10/2024
16.08
16.66
16.90
15.77
Jasper Therapeutics Inc. a clinical-stage biotechnology company develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases such as chronic spontaneous urticaria lower to intermediate risk myelodysplastic syndrome and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
96.9%1 month
84.6%3 months
76.7%6 months
69.9%-
-
2.84
0.02
0.02
-3.42
-
-
-67.01M
242.89M
242.89M
-
-
-
-
-59.32
11.51
12.97
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
8.61
Range1M
8.61
Range3M
9.20
Rel. volume
0.52
Price X volume
1.75M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 1.93 | 265.55M | 0.52% | n/a | 0.00% |
Progenitor Inc | PGEN | Biotechnology | 0.9 | 263.38M | -6.82% | n/a | 14.69% |
Mersana Therapeutics Inc | MRSN | Biotechnology | 2.12 | 260.07M | 3.92% | n/a | 383.37% |
ChromaDex Corporation | CDXC | Biotechnology | 3.38 | 256.65M | -2.59% | n/a | 10.17% |
Poseida Therapeutics Inc | PSTX | Biotechnology | 2.61 | 253.52M | -1.14% | n/a | 137.55% |
Fulcrum Therapeutics Inc | FULC | Biotechnology | 3.82 | 252.91M | -1.29% | n/a | 3.53% |
Amarin Corporation plc | AMRN | Biotechnology | 0.6058 | 249.09M | 0.30% | n/a | 1.47% |
2seventy bio Inc | TSVT | Biotechnology | 4.81 | 247.70M | 0.00% | n/a | 107.07% |
Nanobiotix S.A | NBTX | Biotechnology | 5.19 | 246.03M | 0.00% | n/a | -2742.14% |
Adaptimmune Therapeutics plc | ADAP | Biotechnology | 0.951 | 243.21M | 8.72% | n/a | 49.18% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.42 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 2.84 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 76.70 | 74.67 | Par |
Debt to Equity | 0.02 | -1.82 | Expensive |
Debt to Assets | 0.02 | 0.26 | Cheaper |
Market Cap | 242.89M | 3.73B | Emerging |